Acadia Pharmaceuticals | ACAD - Net Income


Acadia Pharmaceuticals reported $31.5M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
ALKERMES USD 501K 66.98M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Corcept Therapeutics USD 42.14M 73.9M Jun/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
Eisai JPY 18.24B 21.49B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
J&J USD 5.53B 299M Jun/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Prothena USD 32.72M 54.31M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026